In the United States, BSD Medical's products are purchased primarily by medical institutions, which then bill various third-party payers, such as Medicare, Medicaid, other government programs, and private insurance plans, for the health care services provided to their patients, or by managed care organizations, which directly pay for services provided to their patients. The Center for Medicare and Medicaid Services (CMS) has established 23 billing codes that can be used as applicable for or in combination with hyperthermia therapy, depending on the circumstances of the treatment. Appropriate codes apply to billing for superficial, interstitial or deep hyperthermia, when used in combination with ionizing radiation therapy or chemotherapy. Billing codes are available for both the hospital and the oncologist.

In November 1995, HCFA (now CMS) authorized Medicare reimbursement for all investigational therapies and devices for which underlying questions of safety and effectiveness of that device type have been resolved, based on categorization by FDA. All of BSD's investigational (IDE) equipment and protocols have been placed in this category by the FDA, and thus may be reimbursed by Medicare.